Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The majority of patients diagnosed with pancreatic cancer have inoperable disease at the time of presentation. For this reason, systemic treatment is the cornerstone of therapy and more options for systemic therapy have now become available than were a decade ago.
In this short review, we will give an overview on the systemic therapeutic landscape in 2018 and briefly discuss the challenging topic of neoadjuvant therapy.
However, there are a lot of unsolved questions and an urgent need of more clinical trials and new therapies.
In conclusion, despite recent advances, there remains much room for improvement in all aspects of treatment for pancreatic cancer.